1 Chen, L. et al. Inflammatory responses and inflammation-associated diseases in organs. Oncotarget 9, 7204-7218, doi:10.18632/oncotarget.23208 (2018).
2 Grivennikov, S. I., Greten, F. R. & Karin, M. Immunity, inflammation, and cancer. Cell 140, 883-899, doi:10.1016/j.cell.2010.01.025 (2010).
3 Greten, F. R. & Grivennikov, S. I. Inflammation and Cancer: Triggers, Mechanisms, and Consequences. Immunity 51, 27-41, doi:10.1016/j.immuni.2019.06.025 (2019).
4 McGuigan, A. et al. Pancreatic cancer: A review of clinical diagnosis, epidemiology, treatment and outcomes. World J Gastroenterol 24, 4846-4861, doi:10.3748/wjg.v24.i43.4846 (2018).
5 Axelrad, J. E., Lichtiger, S. & Yajnik, V. Inflammatory bowel disease and cancer: The role of inflammation, immunosuppression, and cancer treatment. World J Gastroenterol 22, 4794-4801, doi:10.3748/wjg.v22.i20.4794 (2016).
6 Zhang, X. et al. Risk Factors and Prevention of Viral Hepatitis-Related Hepatocellular Carcinoma. Front Oncol 11, 686962, doi:10.3389/fonc.2021.686962 (2021).
7 Little, A. C. et al. IL-4/IL-13 Stimulated Macrophages Enhance Breast Cancer Invasion Via Rho-GTPase Regulation of Synergistic VEGF/CCL-18 Signaling. Front Oncol 9, 456, doi:10.3389/fonc.2019.00456 (2019).
8 Tian, Z., Hou, X., Liu, W., Han, Z. & Wei, L. Macrophages and hepatocellular carcinoma. Cell Biosci 9, 79, doi:10.1186/s13578-019-0342-7 (2019).
9 Maciel, T. T., Moura, I. C. & Hermine, O. The role of mast cells in cancers. F1000Prime Rep 7, 09, doi:10.12703/P7-09 (2015).
10 Padua, D. & Massague, J. Roles of TGFbeta in metastasis. Cell Res 19, 89-102, doi:10.1038/cr.2008.316 (2009).
11 Mirlekar, B. Tumor promoting roles of IL-10, TGF-beta, IL-4, and IL-35: Its implications in cancer immunotherapy. SAGE Open Med 10, 20503121211069012, doi:10.1177/20503121211069012 (2022).
12 Duan, Z. & Luo, Y. Targeting macrophages in cancer immunotherapy. Signal Transduct Target Ther 6, 127, doi:10.1038/s41392-021-00506-6 (2021).
13 Teixeira, A. F., Ten Dijke, P. & Zhu, H. J. On-Target Anti-TGF-beta Therapies Are Not Succeeding in Clinical Cancer Treatments: What Are Remaining Challenges? Front Cell Dev Biol 8, 605, doi:10.3389/fcell.2020.00605 (2020).
14 Weiss, S. A., Wolchok, J. D. & Sznol, M. Immunotherapy of Melanoma: Facts and Hopes. Clin Cancer Res 25, 5191-5201, doi:10.1158/1078-0432.CCR-18-1550 (2019).
15 Zappavigna, S. et al. Anti-Inflammatory Drugs as Anticancer Agents. Int J Mol Sci 21, doi:10.3390/ijms21072605 (2020).
16 Dinarello, C. A. Anti-inflammatory Agents: Present and Future. Cell 140, 935-950, doi:10.1016/j.cell.2010.02.043 (2010).
17 Bonifant, C. L., Jackson, H. J., Brentjens, R. J. & Curran, K. J. Toxicity and management in CAR T-cell therapy. Mol Ther Oncolytics 3, 16011, doi:10.1038/mto.2016.11 (2016).
18 Cayrol, C. & Girard, J. P. IL-33: an alarmin cytokine with crucial roles in innate immunity, inflammation and allergy. Current opinion in immunology 31, 31-37, doi:10.1016/j.coi.2014.09.004 (2014).
19 Griesenauer, B. & Paczesny, S. The ST2/IL-33 Axis in Immune Cells during Inflammatory Diseases. Frontiers in immunology 8, 475, doi:10.3389/fimmu.2017.00475 (2017).
20 Ameri, A. H. et al. IL-33/regulatory T cell axis triggers the development of a tumor-promoting immune environment in chronic inflammation. Proceedings of the National Academy of Sciences of the United States of America 116, 2646-2651, doi:10.1073/pnas.1815016116 (2019).
21 Park, J. H. et al. Nuclear IL-33/SMAD signaling axis promotes cancer development in chronic inflammation. EMBO J 40, e106151, doi:10.15252/embj.2020106151 (2021).
22 Gabryelska, A., Kuna, P., Antczak, A., Bialasiewicz, P. & Panek, M. IL-33 Mediated Inflammation in Chronic Respiratory Diseases-Understanding the Role of the Member of IL-1 Superfamily. Front Immunol 10, 692, doi:10.3389/fimmu.2019.00692 (2019).
23 Kelsen, S. G. et al. Astegolimab (anti-ST2) efficacy and safety in adults with severe asthma: A randomized clinical trial. J Allergy Clin Immunol 148, 790-798, doi:10.1016/j.jaci.2021.03.044 (2021).
24 Pushparaj, P. N. et al. Interleukin-33 exacerbates acute colitis via interleukin-4 in mice. Immunology 140, 70-77, doi:10.1111/imm.12111 (2013).
25 Luo, P. et al. The IL-33/ST2 pathway suppresses murine colon cancer growth and metastasis by upregulating CD40 L signaling. Biomed Pharmacother 127, 110232, doi:10.1016/j.biopha.2020.110232 (2020).
26 Gao, K. et al. Transgenic expression of IL-33 activates CD8(+) T cells and NK cells and inhibits tumor growth and metastasis in mice. Cancer Lett 335, 463-471, doi:10.1016/j.canlet.2013.03.002 (2013).
27 Pastille, E. et al. The IL-33/ST2 pathway shapes the regulatory T cell phenotype to promote intestinal cancer. Mucosal Immunol 12, 990-1003, doi:10.1038/s41385-019-0176-y (2019).
28 Wang, W., Wu, J., Ji, M. & Wu, C. Exogenous interleukin-33 promotes hepatocellular carcinoma growth by remodelling the tumour microenvironment. J Transl Med 18, 477, doi:10.1186/s12967-020-02661-w (2020).
29 Alonso-Curbelo, D. et al. A gene-environment-induced epigenetic program initiates tumorigenesis. Nature 590, 642-648, doi:10.1038/s41586-020-03147-x (2021).
30 Kawasaki, T. & Kawai, T. Toll-like receptor signaling pathways. Front Immunol 5, 461, doi:10.3389/fimmu.2014.00461 (2014).
31 Nie, L., Cai, S. Y., Shao, J. Z. & Chen, J. Toll-Like Receptors, Associated Biological Roles, and Signaling Networks in Non-Mammals. Front Immunol 9, 1523, doi:10.3389/fimmu.2018.01523 (2018).
32 Zhang, G. & Ghosh, S. Toll-like receptor-mediated NF-kappaB activation: a phylogenetically conserved paradigm in innate immunity. J Clin Invest 107, 13-19, doi:10.1172/JCI11837 (2001).
33 Wicherska-Pawlowska, K., Wrobel, T. & Rybka, J. Toll-Like Receptors (TLRs), NOD-Like Receptors (NLRs), and RIG-I-Like Receptors (RLRs) in Innate Immunity. TLRs, NLRs, and RLRs Ligands as Immunotherapeutic Agents for Hematopoietic Diseases. Int J Mol Sci 22, doi:10.3390/ijms222413397 (2021).
34 Fitzgerald, K. A. & Kagan, J. C. Toll-like Receptors and the Control of Immunity. Cell 180, 1044-1066, doi:10.1016/j.cell.2020.02.041 (2020).
35 Park, J. M. et al. Signaling pathways and genes that inhibit pathogen-induced macrophage apoptosis--CREB and NF-kappaB as key regulators. Immunity 23, 319-329, doi:10.1016/j.immuni.2005.08.010 (2005).
36 Kempe, S., Kestler, H., Lasar, A. & Wirth, T. NF-kappaB controls the global pro-inflammatory response in endothelial cells: evidence for the regulation of a pro-atherogenic program. Nucleic Acids Res 33, 5308-5319, doi:10.1093/nar/gki836 (2005).
37 Wang, A. et al. Transcription factor complex AP-1 mediates inflammation initiated by Chlamydia pneumoniae infection. Cell Microbiol 15, 779-794, doi:10.1111/cmi.12071 (2013).
38 Wen, A. Y., Sakamoto, K. M. & Miller, L. S. The role of the transcription factor CREB in immune function. J Immunol 185, 6413-6419, doi:10.4049/jimmunol.1001829 (2010).
39 Jefferies, C. A. Regulating IRFs in IFN Driven Disease. Front Immunol 10, 325, doi:10.3389/fimmu.2019.00325 (2019).
40 Hu, X., Li, J., Fu, M., Zhao, X. & Wang, W. The JAK/STAT signaling pathway: from bench to clinic. Signal Transduct Target Ther 6, 402, doi:10.1038/s41392-021-00791-1 (2021).
41 Polumuri, S. K. et al. Transcriptional regulation of murine IL-33 by TLR and non-TLR agonists. J Immunol 189, 50-60, doi:10.4049/jimmunol.1003554 (2012).
42 Weinberg, E. O. et al. IL-33 induction and signaling are controlled by glutaredoxin-1 in mouse macrophages. PLoS One 14, e0210827, doi:10.1371/journal.pone.0210827 (2019).
43 Lin, W. R. et al. Granulocyte colony-stimulating factor reduces fibrosis in a mouse model of chronic pancreatitis. PLoS One 9, e116229, doi:10.1371/journal.pone.0116229 (2014).
44 Komar, H. M. et al. Inhibition of Jak/STAT signaling reduces the activation of pancreatic stellate cells in vitro and limits caerulein-induced chronic pancreatitis in vivo. Sci Rep 7, 1787, doi:10.1038/s41598-017-01973-0 (2017).
45 Tsai, S. Y. et al. Regulation of TLR3 Activation by S100A9. J Immunol 195, 4426-4437, doi:10.4049/jimmunol.1500378 (2015).
46 Pruenster, M., Vogl, T., Roth, J. & Sperandio, M. S100A8/A9: From basic science to clinical application. Pharmacol Ther 167, 120-131, doi:10.1016/j.pharmthera.2016.07.015 (2016).
47 Natarajan, C., Yao, S. Y. & Sriram, S. TLR3 Agonist Poly-IC Induces IL-33 and Promotes Myelin Repair. PLoS One 11, e0152163, doi:10.1371/journal.pone.0152163 (2016).
48 Mullen, P. J., Yu, R., Longo, J., Archer, M. C. & Penn, L. Z. The interplay between cell signalling and the mevalonate pathway in cancer. Nat Rev Cancer 16, 718-731, doi:10.1038/nrc.2016.76 (2016).
49 Goldstein, J. L. & Brown, M. S. Regulation of the mevalonate pathway. Nature 343, 425-430, doi:10.1038/343425a0 (1990).
50 Xia, Y. et al. The Mevalonate Pathway Is a Druggable Target for Vaccine Adjuvant Discovery. Cell 175, 1059-1073 e1021, doi:10.1016/j.cell.2018.08.070 (2018).
51 Guerra, C. et al. Chronic pancreatitis is essential for induction of pancreatic ductal adenocarcinoma by K-Ras oncogenes in adult mice. Cancer cell 11, 291-302, doi:10.1016/j.ccr.2007.01.012 (2007).
52 Wang, S. et al. The molecular biology of pancreatic adenocarcinoma: translational challenges and clinical perspectives. Signal Transduct Target Ther 6, 249, doi:10.1038/s41392-021-00659-4 (2021).
53 Kong, B. et al. Dynamic landscape of pancreatic carcinogenesis reveals early molecular networks of malignancy. Gut 67, 146-156, doi:10.1136/gutjnl-2015-310913 (2018).
54 Chen, S. M., Chieng, W. W., Huang, S. W., Hsu, L. J. & Jan, M. S. The synergistic tumor growth-inhibitory effect of probiotic Lactobacillus on transgenic mouse model of pancreatic cancer treated with gemcitabine. Scientific reports 10, 20319, doi:10.1038/s41598-020-77322-5 (2020).
55 Tang, K. et al. Association of Cutaneous Immune-Related Adverse Events With Increased Survival in Patients Treated With Anti-Programmed Cell Death 1 and Anti-Programmed Cell Death Ligand 1 Therapy. JAMA Dermatol 158, 189-193, doi:10.1001/jamadermatol.2021.5476 (2022).
56 Shen, R. R. & Hahn, W. C. Emerging roles for the non-canonical IKKs in cancer. Oncogene 30, 631-641, doi:10.1038/onc.2010.493 (2011).
57 Muvaffak, A. et al. Evaluating TBK1 as a therapeutic target in cancers with activated IRF3. Mol Cancer Res 12, 1055-1066, doi:10.1158/1541-7786.MCR-13-0642 (2014).
58 Cruz, V. H., Arner, E. N., Du, W., Bremauntz, A. E. & Brekken, R. A. Axl-mediated activation of TBK1 drives epithelial plasticity in pancreatic cancer. JCI Insight 5, doi:10.1172/jci.insight.126117 (2019).
59 Moller, M. et al. The Specific IKKepsilon/TBK1 Inhibitor Amlexanox Suppresses Human Melanoma by the Inhibition of Autophagy, NF-kappaB and MAP Kinase Pathways. Int J Mol Sci 21, doi:10.3390/ijms21134721 (2020).
60 Jiang, Y. et al. TANK-Binding Kinase 1 (TBK1) Serves as a Potential Target for Hepatocellular Carcinoma by Enhancing Tumor Immune Infiltration. Front Immunol 12, 612139, doi:10.3389/fimmu.2021.612139 (2021).
61 Zhu, L. et al. TBKBP1 and TBK1 form a growth factor signalling axis mediating immunosuppression and tumourigenesis. Nat Cell Biol 21, 1604-1614, doi:10.1038/s41556-019-0429-8 (2019).
62 Bai, L. Y. et al. BX795, a TBK1 inhibitor, exhibits antitumor activity in human oral squamous cell carcinoma through apoptosis induction and mitotic phase arrest. Eur J Pharmacol 769, 287-296, doi:10.1016/j.ejphar.2015.11.032 (2015).
63 Korherr, C. et al. Identification of proangiogenic genes and pathways by high-throughput functional genomics: TBK1 and the IRF3 pathway. Proc Natl Acad Sci U S A 103, 4240-4245, doi:10.1073/pnas.0511319103 (2006).
64 Wu, J., Leng, X., Pan, Z., Xu, L. & Zhang, H. Overexpression of IRF3 Predicts Poor Prognosis in Clear Cell Renal Cell Carcinoma. Int J Gen Med 14, 5675-5692, doi:10.2147/IJGM.S328225 (2021).
65 Cruz, V. H. & Brekken, R. A. Assessment of TANK-binding kinase 1 as a therapeutic target in cancer. J Cell Commun Signal 12, 83-90, doi:10.1007/s12079-017-0438-y (2018).
66 Jiao, Z. et al. Statin-induced GGPP depletion blocks macropinocytosis and starves cells with oncogenic defects. Proc Natl Acad Sci U S A 117, 4158-4168, doi:10.1073/pnas.1917938117 (2020).
67 Wang, T. et al. Simvastatin-induced breast cancer cell death and deactivation of PI3K/Akt and MAPK/ERK signalling are reversed by metabolic products of the mevalonate pathway. Oncotarget 7, 2532-2544, doi:10.18632/oncotarget.6304 (2016).
68 Nan, X. et al. Ras-GTP dimers activate the Mitogen-Activated Protein Kinase (MAPK) pathway. Proc Natl Acad Sci U S A 112, 7996-8001, doi:10.1073/pnas.1509123112 (2015).
69 Salami, J. A. et al. National Trends in Statin Use and Expenditures in the US Adult Population From 2002 to 2013: Insights From the Medical Expenditure Panel Survey. JAMA Cardiol 2, 56-65, doi:10.1001/jamacardio.2016.4700 (2017).
70 Collins, R. et al. Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet 388, 2532-2561, doi:10.1016/S0140-6736(16)31357-5 (2016).
71 Bear, A. S., Vonderheide, R. H. & O'Hara, M. H. Challenges and Opportunities for Pancreatic Cancer Immunotherapy. Cancer Cell 38, 788-802, doi:10.1016/j.ccell.2020.08.004 (2020).
72 Looi, C. K. et al. Therapeutic challenges and current immunomodulatory strategies in targeting the immunosuppressive pancreatic tumor microenvironment. J Exp Clin Cancer Res 38, 162, doi:10.1186/s13046-019-1153-8 (2019).
73 Lei, A. et al. Atorvastatin promotes the expansion of myeloid-derived suppressor cells and attenuates murine colitis. Immunology 149, 432-446, doi:10.1111/imm.12662 (2016).
74 Tang, T. T. et al. Atorvastatin upregulates regulatory T cells and reduces clinical disease activity in patients with rheumatoid arthritis. J Lipid Res 52, 1023-1032, doi:10.1194/jlr.M010876 (2011).
75 Meng, X. et al. Statins induce the accumulation of regulatory T cells in atherosclerotic plaque. Mol Med 18, 598-605, doi:10.2119/molmed.2011.00471 (2012).
76 Sokalska, A., Hawkins, A. B., Yamaguchi, T. & Duleba, A. J. Lipophilic statins inhibit growth and reduce invasiveness of human endometrial stromal cells. J Assist Reprod Genet 36, 535-541, doi:10.1007/s10815-018-1352-9 (2019).
77 Mira, E. et al. A lovastatin-elicited genetic program inhibits M2 macrophage polarization and enhances T cell infiltration into spontaneous mouse mammary tumors. Oncotarget 4, 2288-2301, doi:10.18632/oncotarget.1376 (2013).
78 Tamburrino, D. et al. Statin use improves survival in patients with pancreatic ductal adenocarcinoma: A meta-analysis. Dig Liver Dis 52, 392-399, doi:10.1016/j.dld.2020.01.008 (2020).
79 Lee, H. S. et al. Statin Use and Its Impact on Survival in Pancreatic Cancer Patients. Medicine (Baltimore) 95, e3607, doi:10.1097/MD.0000000000003607 (2016).
80 Sjoberg, L. C. et al. Interleukin 33 exacerbates antigen driven airway hyperresponsiveness, inflammation and remodeling in a mouse model of asthma. Sci Rep 7, 4219, doi:10.1038/s41598-017-03674-0 (2017).
81 Prefontaine, D. et al. Increased expression of IL-33 in severe asthma: evidence of expression by airway smooth muscle cells. J Immunol 183, 5094-5103, doi:10.4049/jimmunol.0802387 (2009).
82 Schmitz, J. et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity 23, 479-490, doi:10.1016/j.immuni.2005.09.015 (2005).
83 Picelli, S. et al. Full-length RNA-seq from single cells using Smart-seq2. Nat Protoc 9, 171-181, doi:10.1038/nprot.2014.006 (2014).
84 Dobin, A. et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29, 15-21, doi:10.1093/bioinformatics/bts635 (2013).
85 Li, B. & Dewey, C. N. RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome. BMC Bioinformatics 12, 323, doi:10.1186/1471-2105-12-323 (2011).
86 Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol15, 550, doi:10.1186/s13059-014-0550-8 (2014).